Because of the lack of adequate animal models, much of our knowledge of the pathogenesis of primary pulmonary hypertension has come from clinical experiences. The 
.
In the years to come, we will be looking to identify the triggers of endothelial injury in these patients and why some people seem to be predisposed whereas others are not. However, as we understand the nature of the vascular abnormality in these patients and the effects of drugs, more progress in drug treatment and improved survival will be forth¬ coming.
